Skip to content
Screener

NeoGenomics NEO Q1 2026 earnings

Reported April 28, 2026 · After market close

Revenue$186.7MBeat by $2.1M
EPS$0.01Beat by $0.00
Revenue estimate$184.5M
EPS estimate$0.01

Next report

Oct 27, 2026 (in a month)
Revenue estimate$205.9M
EPS estimate$0.06

Financials

Q1 2026

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$963.21M-21.0%
Enterprise value$883.35M-5.6%
P/S1.3×-0.5×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Segments

By product

See full
Client direct billing$131.6M+7.8%
Commercial insurance$30.9M+24.5%
Self-pay-$17.0K-144%

By segment

See full
Reportable Segment$186.7M+11.1%

FAQ

When did NeoGenomics report Q1 2026 earnings?
NeoGenomics (NEO) reported Q1 2026 earnings on April 28, 2026 after market close.
What were NeoGenomics's Q1 2026 revenue and EPS?
NeoGenomics reported revenue of $186.7M and eps of $0.01 for Q1 2026.
Did NeoGenomics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $184.5M by $2.1M. EPS beat the consensus estimate of $0.01 by $0.00.
How did NeoGenomics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.1% from $168.0M a year earlier.
Where can I find NeoGenomics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001077183-26-000022) and the 10-Q periodic report (0001077183-26-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.